Researchers from two Technion faculties have jointly developed a new compound and demonstrated its effectiveness against aggressive tumor cells.

A study published in Oncogene presents an innovative strategy for the particularly complex medical challenge of destroying aggressive, treatment-resistant tumors.

The research was jointly led by early-career scientists Dr. Avital Oknin Vaisman and Dr. Deepanjan Panda from the laboratories of Prof. Amir Orian, head of the Rappaport Center for Cancer Research at the Technion-Israel Institute of Technology and a faculty member in the Ruth and Bruce Rappaport Faculty of Medicine, and Prof. Ashraf Brik of the Schulich Faculty of Chemistry.